1744-859X-8-15 1744-859X Correction <p>Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study</p> Geitona Maria geitona@econ.uth.gr Kousoulakou Hara kousoul@iobe.gr Ollandezos Markos markolan@gmail.com Athanasakis Kostas k.athanasakis@gmail.com Papanicolaou Sotiria spapanic@jacgr.jnj.com Kyriopoulos Ioannis nsph-kyr@ath.forthnet.gr

Department of Economics, University of Thessaly, Magnissias 96, Dionyssos 14576, Greece

Institute for Economic and Industrial Research, Tsami Karatasi 11, 117 42 Athens, Greece

Department of Health Economics, National School of Public Health, Aleksandra's Avenue 196, 11521 Athens, Greece

Janssen-Cilag Pharmaceutical SACI, Eirinis Avenue 56, 15121 Pefki, Athens, Greece

 Annals of General Psychiatry 1744-859X 2009 8 1 15 http://www.annals-general-psychiatry.com/content/8/1/15 1953872610.1186/1744-859X-8-15 17 6 2009 18 6 2009 18 6 2009 2009 Geitona et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008, 7:16. This correction reports changes in the values listed for Ziprasidone and Aripiprazole in Table Ten.

Correction

Following the publication of our article 1, it has come to our attention that there was an error with the values listed for Ziprasidone and Aripiprazole in Table Ten. Table Ten should therefore appear as shown in this correction (Table 1).

<p>Table 1</p>

Mean annual number of stable days and cost per patient by pharmaceutical treatment.

Paliperidone ER

Olanzapine

Risperidone

Quetiapine

Ziprasidone

Aripiprazole

Base case:

Cost (€)

7.030

7.034

7.082

8.321

7.807

7.713

Effectiveness

272.5

272.2

265.5

260.7

258.6

260.5

Incremental cost and effectiveness compared with paliperidone ER:

Cost (€)

-

4

52

1.291

777

683

Effectiveness

-

-0.3

-7.0

-11.8

-13.9

-12.0

 <p>Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study</p> Geitona M Kousoulakou H Ollandezos M Athanasakis K Papanicolaou S Kyriopoulos I Annals of General Psychiatry 2008 7 16 2553072 18755025 10.1186/1744-859X-7-16